Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05703971 · ClinicalTrials.gov registry record · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
A Phase 1 study of Small Cell Lung Cancer Extensive Stage, sponsored by Genprex.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 17
- Study locations
NCT05703971: Recruiting Phase 1 study of Small Cell Lung Cancer Extensive Stage, sponsored by Genprex.
NCT05703971 is a Phase 1 study of Small Cell Lung Cancer Extensive Stage that is actively recruiting participants, run by Genprex. The registered enrollment target is 62 participants, above the 37-participant average among 3 other Small Cell Lung Cancer Extensive Stage trials with a reported enrollment target (68% higher). The trial reports 17 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05703971, a Phase 1 study of Small Cell Lung Cancer Extensive Stage, is actively recruiting participants, sponsored by Genprex.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 17
- Study locations
Study Summary
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Primary Outcome
The MTD and/or RP2D of the combination of quaratusugene ozeplasmid and atezolizumab. Note: if a MTD is not determined, the RP2D will be selected based on all available data (safety, PK, PD, and preliminary efficacy).
Conditions Studied
Interventions
- BIOLOGICAL quaratusugene ozeplasmid
- BIOLOGICAL atezolizumab
Study Locations (17)
Ohio
- Gabrail Cancer Center Research - Canton
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Cincinnati
- Oncology_Hematology Care Clinical Trials, LLC - Fairfield
Oregon
- Willamette Valley Cancer Institute (Oregon) - Eugene
- Northwest Cancer Specialists, P.C. - Portland
- Providence Cancer Institute - Portland
- Northwest Cancer Specialists, P.C. - Portland
- Northwest Cancer Specialists, P.C. - Tigard
Texas
- Texas Oncology - DFW - Dallas
- Texas Oncology - Northeast Texas - Tyler
Colorado
- Rocky Mountain Cancer Centers, LLP - Lone Tree
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
Virginia
- Virginia Cancer Specialists, PC - Fairfax
Washington
- Northwest Cancer Specialists, P.C. - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT05703971 shows while recruiting
NCT05703971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, above the 37-participant average among 3 other Small Cell Lung Cancer Extensive Stage trials with a reported enrollment target (68% higher).
The record links to 1 condition, with Small Cell Lung Cancer Extensive Stage appearing as the primary indexed condition, and to 2 interventions - of which quaratusugene ozeplasmid is the first listed.
NCT05703971 lists 17 locations in 7 states (Ohio, Oregon, Texas).
Frequently Asked Questions
What is clinical trial NCT05703971 about?
NCT05703971 is a clinical study titled "Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients". This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase ...
What is the current status of trial NCT05703971?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2024-05-09. Estimated completion is 2027-08.
What conditions does trial NCT05703971 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer Extensive Stage.
What interventions are being tested in trial NCT05703971?
The interventions under investigation include: quaratusugene ozeplasmid (BIOLOGICAL), atezolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05703971?
This trial is sponsored by Genprex, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05703971 being conducted?
This trial has 17 study locations across Colorado, Missouri, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer Extensive Stage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
RECRUITING · Phase 1
-
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
RECRUITING · Phase 1
-
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI